BEYONDSPRING INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.33 USD | 0.00% |
|
+3.56% | +158.89% |
| Apr. 29 | North American Morning Briefing : Investors Brace -2- | DJ |
| Apr. 22 | North American Morning Briefing : Stock Futures -2- | DJ |
Presentation Operator MessageOperator (Operator)Good morning. And welcome to BeyondSpring's Se...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for the debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.
Calendar
2024-05-15
- R&D Day
| 1st Jan change | Capi. | |
|---|---|---|
| +158.89% | 90.91M | |
| +3.15% | 108B | |
| +10.38% | 104B | |
| +0.32% | 22.33B | |
| -11.70% | 22.19B | |
| -7.05% | 18.69B | |
| -38.36% | 17.74B | |
| -9.13% | 17.64B | |
| +6.41% | 14.05B | |
| +37.17% | 12.51B |
- Stock Market
- Equities
- BYSI Stock
- News BeyondSpring Inc.
- Transcript : BeyondSpring Inc., Q2 2020 Earnings Call, Sep 03, 2020